Veterinary, pediatric, research, and pharma leaders are speaking during the Canines-N-Kids Foundation’s
Paws for a Cure Research Symposium being held on November 12-13, 2018 at the Merck Research Laboratories in Boston. The final agenda
explores ways these medical research communities can collaborate to speed cancer drug development for cancers shared by kids and pet dogs. In addition, the V Foundation for Cancer Research
, a top-rated cancer research charity, and the Parker Institute for Cancer Immunotherapy
, which coordinates cancer research efforts between leading scientists, clinicians and partners in the industry, have joined as Title Sponsor and Contributing Sponsor, respectively for the symposium.
“We have heavy hitters lined up to speak during Paws for a Cure—all prepared to discuss a unique opportunity to help children and pets overcome serious cancers that afflict both. We believe bringing together top-notch support from the V Foundation, together with Petco Foundation, Blue Buffalo and the Parker Institute, who are dedicated to helping one or the other, has real potential to accelerate progress for both kids and dogs with cancer,” explained Ulrike Szalay, founder and executive director, Canines-N-Kids Foundation, a nonprofit committed to promoting and funding research for comparative oncology that integrates efforts for the benefit of both kids and dogs with cancer.
Keynotes by Michael Kastan, M.D. Ph.D., Pediatric Oncologist, Executive Director of the Duke Cancer Institute and Board Member of the V Foundation, and Lee J. Helman, M.D., Pediatric Oncologist, Keck School of Medicine, University of Southern California; Head, Basic and Translational Research, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, will set the stage for the event that includes several panels and presentations by top experts in the fields. Topics include:
- Can human and pediatric oncology drug development be accelerated by integrating the canine patient?
- Comparative Oncology Toolbox: Progress, Challenges, and Next Steps
- Comparative Genomics: Advances and Precision Medicine
- Advances in Comparative Immunology
- Regulatory Environment and Bioethics
- Courageous Warriors: Cancer Patients’ Perspectives
- Comparative Imaging
- Collaborations at Both Ends of the Leash: Examples in Ongoing Clinical Trials & Research
- Infrastructure for Comparative Cancer Research and Complementing for Collaboration
- Challenges in Drug Development & the Integration of the Canine Cancer Patient
- Priorities for Accelerating Cancer Drug Development
With support from title sponsors, the V Foundation and the Petco Foundation
in partnership with the Blue Buffalo Foundation, the symposium will convene experts to discuss advancing research in pediatric cancer treatments, including how to use comparative approaches to make progress in this field. The meeting will bring together pediatric oncologists; veterinary oncologists; translational research scientists in academia and in industry; pharma and biotechnology professionals in preclinical research, drug development, oncology and animal health; as well as nonprofits and other funders.
Both children and canine companions spontaneously develop a number of cancers with remarkable similarities. The challenges inherent in designing and implementing pediatric oncology clinical trials for the 16,000 children with cancer, coupled with only four percent of federal cancer research funding going towards pediatric cancer research, makes finding cures difficult. In addition, little pharmaceutical industry funding goes to pediatric cancer research and as a result only four new medications have been approved for the treatment of pediatric cancer in the last 30 years. For the six million dogs diagnosed with cancer in the US each year, the outlook is not much better. The Paws for a Cure Research Symposium continues the conversation of the integrations of drug development in pediatric and pet population to greatly accelerate the discovery of novel, more effective, less toxic treatments for these cancers.
The Symposium is also backed by the American Cancer Society, the Rally Foundation for Childhood Cancer Research, Boehringer Ingleheim Animal Health, Anivive and Applied Biomath, and The Parker Foundation. Admission is $949 for industry and $699 for academic/nonprofit attendees. Registration information, as well as featured speakers and topics can be found at http://www.pawsforacuresymposium.com/agenda